The recent article by Gheeraert et al. (1) was interesting and thought-provoking. The authors suggested that acute occlusion of the left-side coronary vessels (left anterior descending [LAD] or left circumflex [Lcx] arteries) increases the risk of out-of-hospital ventricular fibrillation (VF) in acute myocardial infarction (AMI) patients. The study was designed so that they compared patients who were successfully resuscitated from VF found to be due to AMI and AMI patients without VF. Their conclusions, however, raise points of criticism.
The resuscitated patients they studied with angiography were those in whom there was a reasonably short period from the loss of consciousness to the beginning of resuscitation to assure that these patients had a chance of surviving without major neurologic deficits. The authors also discuss the possible limitation by selection bias because a great majority of patients with out-ofhospital VF fall short of reaching their series (2) . However, they hypothesize that there is no bias without referring to previous studies on sudden cardiac death (SCD) victims.
The authors found that only 15% of occlusions in those AMI patients succesfully resuscitated from VF were situated in the right coronary artery (RCA). This finding is contradicted by the fact that numerous studies on SCD victims with AMI have shown that RCA is the culprit occluded artery in 40 to 50% of cases (2) (3) (4) (5) . One study even addressed the issue of coronary and myocardial findings in SCD victims compared with hospital AMI patients (3) and found that inferior infarctions and RCA occlusions were more frequent in SCD victims.
It is, thus, highly likely that the results of Gheeraert et al. (1) are the consequence of selection bias. Their conclusion that RCA occlusion is associated with decreased risk of arrhythmia is also highly speculative in light of the patient selection and the results of previous studies on SCD. In asymptomatic individuals who suffer AMI, the degree of the underlying coronary disease is the most severe in the left-sided vessels, especially LAD (6). Thus, collaterals are possibly more frequently supplying the myocardium normally fuelled by LAD, and the total occlusion of RCA is likely to be associated with severe arrhythmic response in the absence of significant collaterals (7) .
The major conclusion from the results presented in the study by Gheeraert et al. is that left-side coronary occlusion may, in fact, be associated with decreased risk of dying suddenly in the acute phase of AMI and select individuals who are more likely to be resuscitated succesfully by the paramedics and ultimately reach the hospital and qualify for study series, such as the one commented on here.
REPLY
We thank J. Mikkelsson for his comments on our article (1). The authors would like to take this opportunity to discuss the effects of patient selection and points of interest in more detail when our results are compared with studies on sudden cardiac death (SCD).
We studied out-of-hospital ventricular fibrillation (VF) in the early phase of acute myocardial infarction (AMI). To compare our study with studies on SCD, two main points deserve attention. First, we focused on the early phase of AMI. In victims of SCD identification of subjects that were in the early phase of AMI is extremely challenging. Standard histological techniques underestimate the true frequency of early AMI. The articles on SCD cited by Mikkelsson confirmed that only 5 to 21% of victims were in the early phase of AMI. Presence of a fresh coronary occlusion or ruptured plaque also varied between 23 and 82%, reflecting heterogeneity of methodology or studied populations. Diagnosis of early phase of AMI in our study was based on ST segment elevation and angiographically confirmed presence of a fresh coronary occlusion. Identical criteria were applied for the control group. Second, we specifically focused on VF and not on all fatal arrhythmias as a whole. Severe bradyarrhythmias are reported up to 30% in SCD (2) . In studies on SCD the fatal arrhythmia is seldom specified. In our study VF was confirmed by rhythm recordings. So, studies on SCD are impossible to compare with our study as long as VF, early phase of AMI and coronary anatomy are not simultaneously specified.
The main finding of our study was that acute occlusion in the left coronary artery is associated with greater risk for out-ofhospital VF compared with the right coronary artery in the early phase of AMI. This finding is not the result of differential selection. We fully agree that the AMI patients in our study do not represent all patients with AMI. To reach the group of "AMI with VF," patients had to survive VF. To explain our findings by selection bias, as suggested by Mikkelsson, one has to assume that patients with out-of-hospital VF and occlusion of left coronary artery have a higher probability of being admitted than patients with out-of-hospital VF and occlusion of right coronary artery. To the best of our knowledge, there are no data suggestive of this assumption.
The comments of Mikkelsson and our article raise another important field of interest: What is the effect of site of occlusion on life-threatening bradyarrhythmias in the early phase of AMI? Therefore, studies on SCD that document bradyarrhythmias, early phase of AMI and coronary anatomy would be very interesting.
Underestimation of the Valvulopathy Effect of Fenfluramine
In an effort to evaluate the relationship between the use of fenfluramines as diet drugs and the prevalence of mitral valve and aortic valve regurgitation, Burger et al. (1) compared measurements from a study conducted for another purpose to those described by Singh (2) . Burger observed that the prevalence of mitral valvulopathy in his study was comparable with the Framingham study (1.3% vs. 1.6% from Framingham) and aortic regurgitation (6.6% vs. 4.8% from the Framingham study). Burger surmised that the valvulvar regurgitation seen in his patients may not be due to fenfluramine but to age-related degenerative changes. Schiller (3), in an accompanying editorial, seconds this point of view stating (page 1161), "It would seem then that as studies have become more scientifically rigorous, the role of fen/phen in valve disease appears to be approaching the vanishing point." However, there are two important additional observations concerning Burger's methodology that undermine these conclusions.
There were 591 patients in Burger's study. Of these patients, only 226 (38.2%) returned for an echocardiogram. The remaining 365 patients who were also exposed to the fenfluramines, for unknown reasons, did not undergo echocardiography. Since only three of the 226 patients who returned had mitral regurgitation, and only 15 of the 226 patients had aortic regurgitation, the fate of the remaining 365 patients is critical in a proper assessment. The absence of the echocardiograms in over 60% of the cohort makes this study especially vulnerable to selection bias.
A second concern involves Burger's simple comparison between regurgitation prevalence in his population and Framingham. The difference in the mean ages between that of Burger's cohort (mean age 46.9, standard deviation 8.9) and that of the Framingham population (mean age 55, standard deviation 10) suggests that a coarse comparison of the crude prevalences from these two populations is inappropriate and misleading. Fortunately a more appropriate adjustment is available through an examination of Singh's data (4). Given both the mean age (standard deviation) and the gender distribution provided by Burger one can, assuming the normal distribution, approximate the distribution of age and gender in the Burger study. From Singh (4) the prevalence of each of mitral regurgitation and aortic regurgitation is available (Table 1) .
From Table 1 one can compute the expected prevalence in the Burger cohort based on the gender and age-specific mitral and aortic valve prevalence in the Framingham study. If the 10.2% of patients whose ages are outside the 26 to 83 age range (based on a normal distribution with mean age 46.9 and standard deviation 8.9) fall in the upper age range (greater than 83) and these patients have the same prevalence of valvular regurgitation as those in the 70 to 83 age range, the computations reveal that the expected prevalence for mitral regurgitation (Food and Drug Administration criteria) is 1.0% and for aortic regurgitation is 3.3%. This conservative computation provides mitral and aortic prevalences that are less than those observed by Burger. Based on these ageand gender-adjusted prevalences, the prevalences seen by Burger et al. are greater than would be expected from degenerative changes alone.
These two observations substantially weaken the explanation provided by Burger. Since Schiller chose to build his conclusions on Burger's results, this editorial's foundation is now effectively removed. The data collected by Burger, while representing an incomplete assessment, support, rather than refute, the association found between fenfluramine and cardiac valvulopathy. 
